Company News
05/03/2021
Aditxt to Establish State-of-the-Art Immune Monitoring Center in Virginia Bio+Tech Park »
Aditxt (Aditx Therapeutics, Inc.) a biotech innovation company focused on improving the health of the immune system, announced plans to build a high-capacity AditxtScore™ Center in the Virginia Bio+Tech Park in Richmond, VA in the second half of 2021.
05/03/2021
RIVANNA® Announces Alliance With Tri-anim Health Services
RIVANNA®, developers of world-first, imaging-based medical solutions, announced they have entered into a partnership with Tri-anim Health Services, a specialty distributor of respiratory, anesthesia, and critical-care supplies, to represent and distribute the Accuro® portfolio of products in the United States.
05/03/2021
Aditxt to Establish State-of-the-Art Immune Monitoring Center in Virginia Bio+Tech Park
Aditxt (Aditx Therapeutics, Inc.) a biotech innovation company focused on improving the health of the immune system, announced plans to build a high-capacity AditxtScore™ Center in the Virginia Bio+Tech Park in Richmond, VA in the second half of 2021. Aditxt is targeting a capital investment of $31.5 million over three years to scale up its …
05/03/2021
RIVANNA® Announces Alliance With Tri-anim Health Services
RIVANNA®, developers of world-first, imaging-based medical solutions, announced they have entered into a partnership with Tri-anim Health Services, a specialty distributor of respiratory, anesthesia, and critical-care supplies, to represent and distribute the Accuro® portfolio of products in the United States. RIVANNA announced a partnership with Tri-anim Health Services Tri-anim is a natural distribution choice for …
05/03/2021
Children’s National Research & Innovation Campus Welcomes New Resident Company, AlgometRx to JLABS
AlgometRx Inc., a Children’s National spinout company developing a handheld device to objectively measure pain by pupillary response, will relocate to Johnson & Johnson Innovation – JLABS @ Washington, DC on the Children’s National Research & Innovation Campus.
04/29/2021
ReAlta Life Sciences Closes $20M Series A3 Financing to Advance Multiple Programs into Phase 2 Trial
ReAlta Life Sciences, Inc., announced that the Company has successfully closed a Series A3 financing of $20 million. The financing was led by Marathon Pharma, with support from existing Series A investors and new, undisclosed investors.